Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab for arterial wall inflammation after acute coronary syndrome
NL-OMON39440Phase 2Active, not recruiting
- Sponsor
- IRIS
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gevokizumab in atherosclerosis and arteritis (4 arms), sponsored by IRIS. Primary endpoints: Change from baseline in mean of the maximum target-to-background ratio, Change from baseline in average mean target-to-background ratio and 2 more. Started Jan 2013; status: active, not recruiting.
02
Drugs
gevokizumab
03
Conditions
atherosclerosisarteritis
Beyond the preview
Go deeper on NL-OMON39440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39440.